热门资讯> 正文

Vaxcyte GAAP每股收益-1.56美元，相差0.25美元

2025-11-05 06:23

Vaxcyte(PCVX) 0
Strategy (MSTR) 0

Vaxcyte press release (PCVX): Q3 GAAP EPS of -$1.56 misses by $0.25.
Ending the third quarter with $2.7 billion in cash, cash equivalents and investments.

More on Vaxcyte

Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript
ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE
Vaxcyte teams up with Thermo Fisher to ensure future vaccine production
Seeking Alpha’s Quant Rating on Vaxcyte
Historical earnings data for Vaxcyte

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。